Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA
Julie M. Shabto , Dylan J Martini , Yuan Liu , Deepak Ravindranathan , Meredith R Kline , Elise Hitron , Greta Russler , Sarah Caulfield , Haydn Kissick , Mehrdad Alemozaffar , Kenneth Ogan , Wayne Harris , Viraj A. Master , Omer Kucuk , Bradley Curtis Carthon , Mehmet Asim Bilen
Background: Several IO agents have been approved for treatment of advanced urothelial cancer pts. We investigated the association between sites of mets and CO in urothelial cancer pts treated with IO in the real world setting. Methods: We performed a retrospective review of 67 urothelial cancer pts treated with PD-1 or PD-L1 inhibitors at Winship Cancer Institute from 2015-2018. Overall survival (OS) and progression free survival (PFS) were measured from first dose of IO to date of death or hospice referral and radiographic or clinical progression, respectively. Sites of mets were collected from radiology and clinic notes at baseline. Univariate analysis (UVA) and multivariable analysis (MVA) used Cox proportional hazard. Results: The median age was 70 and most (79.1%) were men. Pts had mets to sites such as lymph node (73.1%), bone (29.9%), liver (20.9%), lung (31.3%), and brain (1.5%). Pts with bone or liver mets had significantly shorter OS and PFS in UVA. Pts with bone mets also had significantly shorter OS and PFS in MVA (Table). The median OS of pts with bone mets was 2.2 months (12-month survival=28.0%), while those without bone mets had a median OS of 21.9 months (12-month survival=52.5%) per Kaplan-Meier estimation. The median OS of pts with liver mets was 2.2 months (12-month survival=28.6%), while those without liver mets had a median OS of 12.8 months (12-month survival=50.1%) per Kaplan-Meier estimation. Conclusions: Bone and liver mets are poor prognostic factors in urothelial cancer pts receiving IO in the real world setting. These findings should be validated in a larger study.
UVA | MVA | |||||||
---|---|---|---|---|---|---|---|---|
OS | PFS | OS | PFS | |||||
HR (CI) | p-value | HR (CI) | p-value | HR (CI) | p-value | HR (CI) | p-value | |
Bone mets: No (n=47) vs. Yes (n=20) | 0.37 (0.19-0.73) | 0.004* | 0.46 (0.25-0.82) | 0.009* | 0.21 (0.09-0.47) | <0.001* | 0.33 (0.16-0.69) | 0.003* |
Liver mets: No (n=53) vs. Yes (n=14) | 0.39 (0.19-0.82) | 0.013* | 0.46 (0.25-0.82) | 0.009* | 0.56 (0.18-1.73) | 0.313 | 0.72 (0.30-1.79) | 0.492 |
†The multivariable model controlled for race, age, ECOG performance status, number of metastatic sites, baseline albumin and baseline hemoglobin. *statistical significance at alpha < 0.05
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Wenxiao Jia
2023 ASCO Annual Meeting
First Author: Montaser F. Shaheen
2023 ASCO Annual Meeting
First Author: Dimpal M. Kasabwala
2022 ASCO Annual Meeting
First Author: Yu-Wei Chen